Clinical Trial

Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures

Enrolling by Invitation Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 30, 2025 (before its estimated November 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical study has two objectives. The Primary Objective is to evaluate the effectiveness of microdosed GLP-1 receptor agonists in improving measures of health, quality of life, and longevity. The Secondary Objective: To assess the impact of these therapies on weight management practices and metabolic health.
Trial Details
NCT Number NCT07092605
Lead Sponsor AgelessRx
Conditions Longevity, Quality of Life, Mood, Inflammation, Immune Health, Pain Management, Weight Management, Alertness
Enrollment 150 participants
Start Date 2024-11-01
Primary Completion 2025-11-01 (estimated)
Study Completion 2025-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-30